Breast cancer is a significant health concern affecting millions of women worldwide. In recent years, germline genetic testing has become an integral part of clinical care for women with breast cancer, particularly those with a known BRCA1 mutation. However, the optimal treatment approach for these patients remains uncertain. A recent international analysis presented at the San Antonio Breast Cancer Symposium suggests that bilateral mastectomy as the initial treatment may not be associated with improved survival in this population. This article critically evaluates the study findings and their implications for clinical practice.
The analysis conducted by Kelly Metcalfe and colleagues included 2,482 women from 26 centers in 11 countries, all of whom had a documented BRCA1 pathogenic variant and a diagnosis of stage I-III breast cancer. The results revealed that bilateral mastectomy was not significantly associated with a reduction in mortality compared to breast-conserving treatment (HR 0.83, P=0.52). The rates of 15-year breast cancer-specific survival were 86.2% with breast-conserving treatment, 78.7% with unilateral mastectomy, and 88.7% with bilateral mastectomy. These findings challenge the prevailing belief that bilateral mastectomy offers a survival advantage in women with breast cancer and a BRCA1 mutation.
Risk of Contralateral Breast Cancer
Although bilateral mastectomy did not improve overall survival, it was associated with a lower likelihood of developing contralateral breast cancer during follow-up. The incidence of contralateral breast cancer was significantly lower in the bilateral mastectomy group (0.8%) compared to the breast-conserving treatment group (10.8%) and the unilateral mastectomy group (11.4%) (PIncreased Risk of Mortality in Contralateral Breast Cancer
The analysis also revealed that women who developed contralateral breast cancer were twice as likely to die compared to those who did not (HR 2.22, PChallenges in Personalized Treatment
The integration of germline genetic testing into clinical care has allowed for personalized treatment approaches based on individual risk profiles. However, women with a BRCA1 mutation face unique challenges that extend beyond the index cancer. In addition to the increased risk of contralateral breast cancer, these patients also have a high lifetime risk of developing ovarian cancer. Therefore, treatment decisions must consider these multiple risks comprehensively.
Despite the study’s findings, some experts maintain their recommendation for bilateral mastectomy in women with a known BRCA1 mutation, particularly younger patients who are at higher risk of developing a second cancer. Dr. Brian Czerniecki from the Moffitt Cancer Center in Tampa, Florida, emphasized the potential benefits of bilateral mastectomy in preventing second cancers and improving life expectancy. He noted that subsequent cancers that develop are likely to be triple-negative breast cancers, which are challenging to treat. Therefore, the decision to undergo bilateral mastectomy should be made on an individual basis, considering the patient’s age, overall health, and personal preferences.
It is essential to recognize the limitations of the analysis conducted by Metcalfe and colleagues. The study involved retrospective data collection from medical records, introducing inherent biases and potential confounding factors. Additionally, the relatively small sample size and shorter follow-up period limit the generalizability of the findings. To address these limitations, the investigators aim to continue accruing data, with a projected sample size of 6,000.
Future studies should also focus on evaluating the efficacy and potential side effects of newer treatments such as olaparib (Lynparza), a poly (ADP-ribose) polymerase (PARP) inhibitor, which has shown promise in BRCA-mutated breast cancer. Furthermore, the benefit of oophorectomy, which has been shown to be protective against mortality, should be carefully considered. These advances in treatment options may further inform personalized treatment decisions for women with breast cancer and a BRCA1 mutation.
Bilateral mastectomy as the initial treatment for women with breast cancer and a pathogenic BRCA1 variant does not appear to confer a significant survival advantage compared to breast-conserving treatment. However, it may reduce the risk of contralateral breast cancer development. Given the complex considerations involved in managing this high-risk population, a multidisciplinary approach is necessary to individualize treatment decisions. Ongoing research and advancements in targeted therapies hold promise for improving outcomes and reducing mortality in women with breast cancer and a BRCA1 mutation.
Leave a Reply